J. Keith Joung

J. Keith Joung is a leading innovator in the field of genome editing. He is currently Desmond and Ann Heathwood Research Scholar, Pathologist, and Associate Chief of Pathology for Research at Massachusetts General Hospital (MGH) and is Professor of Pathology at Harvard Medical School. He is also a member of the Center for Cancer Research and the Center for Computational and Integrative Biology at MGH.

Dr. Joung has been a pioneer in the development of important technologies for targeted genome editing and epigenome editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the MGH Research Scholar Award, an NIH R35 MIRA (Maximizing Investigators Research Award), election into the American Association of University Pathologists, and designation as a “Highly Cited Researcher” in 2016 and 2017 by Thomson Reuters/Clarivate Analytics. He serves on the Board of Directors for the American Society of Gene and Cell Therapy (ASGCT) and the editorial boards of Genome Biology, Human Gene Therapy, and Trends in Biotechnology.

Dr. Joung has co-founded and continues to advise multiple biotechnology companies, including Editas Medicine, Beam Therapeutics, Pairwise Plants and Verve Therapeutics.

Dr. Joung holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School and an A.B. in biochemical sciences from Harvard College.